State Leaders and International Cyber Experts Convene for CyberTech in Israel, Tel Aviv 26-27 January

 


Israeli Prime Minister Benjamin Netanyahu, State Leaders from around the world, Global Cyber Security executives and Investors will take part in the second largest exhibition of cyber technologies worldwide


Hundreds of delegations from across the globe will attend CyberTech, including a large delegation from Japan, a US delegation led by the Deputy Secretary of Homeland Security, a delegation from developing countries organized by the World Bank, as well as a Canadian delegation comprising Senior Executives of Canada's Central Banks


Distinguished international speakers in the field of cybersecurity will discuss a variety of subjects including an exclusive panel discussion with The World Federation of Exchanges (WFE) on the topic of security and cyber threats and a conference with electric companies from around the world led by the Israel Electric Corporation (IEC)


Convening January 26-27, 2016, at the Israel Trade Fairs & Convention Center, Pavilion 2


The CyberTech 2016 Conference held for the third year in Israel at the Israel Trade Fairs and Convention Center, Pavilion 2 on the 26-27 of January is the most significant conference and exhibition of cyber technologies outside of the United States. CyberTech will bring together leading multi-national corporations, startup companies, major Israeli companies, investors, entrepreneurs, distinguished international speakers in the field of cyber security as well as an exhibition hosting over 250 companies and 100 startups to present innovative problem solving strategies and solutions to challenges in a wide range of sectors.


Israeli Prime Minister Benjamin Netanyahu, who launched the Israel National Cyber authority devoted entirely to cyberwarfare, will open the CyberTech Conference as the keynote speaker. Opening the conference alongside Prime Minister Benjamin Netanyahu will be the Head of the National Cyber Bureau in the Prime Minister office of Israel, Dr. Eviatar Matania, President and CEO of CyberArk, Udi Mokady and senior executives of HP and IBM.


The CyberTech Conference will host other prominent speakers, including Israel's Minister of National Infrastructure, Energy and Water, Dr. Yuval Steinitz, the Israeli Minister of Science, Ofir Akunis, distinguished Governors, Ministers and senior executives from around the world and global cybersecurity leaders. Member of Knesset and Head of the Cybersecurity lobby in the Israeli Parliament, Erel Margalit will lead a discussion on cyber in the presence of member of parliaments from across the world. CyberTech will hold a Start-Up Pavilion presenting the 10 most promising and innovative Israeli start-ups from the field of cyber and will host the first 'hacker meeting' in Israel.


Hundreds of delegations from around the world, major corporations and international investors will attend the event to learn about the breakthroughs in cyber technologies achieved by innovative Israeli companies, including a large delegation from Japan, attending the exhibition to find suitable technologies to secure the Tokyo Olympics 2020 from potential cyber threats as well as a delegation from the US headed by the deputy Secretary of Homeland Security, Alejandro Mayorkas, a large delegation from developing countries organized by the World Bank and a Canadian delegation comprising the Senior Executives of Canada's central banks, as well as delegations from Germany, the UK, Italy, Holland, France, Australia, Singapore, Hong Kong, Taiwan, India, South Korea, Vietnam, the Philippines, Mexico, Brazil, Argentina, Kenya, South Africa, Ecuador, Panama, Guatemala, Colombia, Sweden, Ireland, Spain, Czech Republic, Romania, Albania, Estonia, the EU and NATO.
The event will provide a unique platform for discussion about the latest technological developments related to cyber protection, security and the growing popularity of cyber media, including an exclusive panel discussion with The World Federation of Exchanges (WFE) on the topic of security and cyber threats in the global stock exchange markets and a panel hosting electric companies from around the world led by the Israel Electric Corporation (IEC).


In addition to the unique opportunity to learn about and discover the latest innovations in the cyber field, CyberTech presents problem solving strategies and solutions to challenges in a wide range of sectors including finance, defense, transportation,utilities, R&D, energy, manufacturing, service sectors, health, media, government, and more.

 

The event will allow B2B, startups, investors, government officials, military personnel, ambassadors and exhibition visitors to focus on networking, strengthening existing alliances, and forming new ones.


This year for the first time ever, two large CyberTech Conferences took place in Singapore and Toronto. An additional CyberTech Conference will take place in Los Angeles in April 2016.


http://www.cybertechisrael.com/


CyberTech 2015: https://www.youtube.com/watch?v=l1bHb6BZbJg

 

 

 

 Photos provided by The CyberTech 2016 Conference  PR

 

 

 

 

 

Add a comment

 

 

In recent weeks, two extraordinary stroke cases were successfully treated at Haifa’s Rambam Health Care Campus, thanks to a unique, time-saving “Red Carpet Treatment.”

 

The first patient, a 93-year-old woman, made history as the oldest stroke victim in Israel to successfully undergo mechanical thrombectomy to remove the blockage in her brain. Admitted to Rambam, she received the fast-track Red Carpet Treatment for suspected stroke patients under the supervision of Professor Gregory Talman of the Department of Neurology and Dr. Yaakov Amsalem, Director of the Interventional Neuroradiology Unit. One day after surgery the patient was fully functioning and laughing with her family.

 

In the second case, a 67-year-old Gazan woman was at Rambam visiting her grandson when she suffered a stroke. Seeing that something was terribly wrong, the boy called for help. Upon transferring her to the emergency department it was learned she had suffered an ischemic stroke with a total blockage of the artery that supplies blood and oxygen to the left side of her brain. For her too, a mechanical thrombectomy was considered the best approach.

 

“The patient was lucky to be here when she had the stroke,” said Dr. Amsalem. “Time is a critical factor, and the needed treatment she needed just happened to be available. From the moment she reached our emergency department to the time the blockage was cleared, an hour and 15 minutes passed—record time for patients like this.”

 

Mechanical thrombectomy is a complex and delicate procedure. A catheter is guided to the blockage site, and the thrombus is “captured” and removed by means of a specially fitted stent. This treatment is available in only six hospitals in Israel—Rambam is one of them. This procedure is yet another example of how state-of-the-art interventional approaches are transforming the standard of health care and saving precious lives.

 

 Photo : Inessa Azarov and Prof. Gregory Teleman by Pioter Fliter

 

 

 

 

 

Add a comment

 

 

Innovative drug for treating prostate cancer approved in Mexico

 

A successful Phase III clinical trial in Latin America, involving 80 patients, confirmed the high rate of local cures and minimal side effects, as evidenced by negative biopsies and maintenance of patients’ potency, continence and quality of life

 

A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (Luxembourg) has been approved by Cofepris, Mexico’s health authority, for the focal treatment of early-stage prostate cancer.

 

The therapy involves a laser and a novel drug, TOOKAD® Soluble. A successful Phase III clinical trial in Latin America (Mexico, Peru and Panama), involving 80 patients, confirmed the high rate of local cures and minimal side effects already reported in Phase II clinical trials, as evidenced by negative biopsies and maintenance of patients’ potency, continence and overall quality of life.

 

The marketing approval in Mexico comes in the wake of the recent completion of a second Phase III clinical trial in Europe. This randomized pivot study compared disease progression, cancer-free rate and urinary and erectile functions in patients treated with TOOKAD® Soluble and those undergoing active surveillance with a follow-up of two years. It involved more than 400 patients at 43 hospitals in 11 European countries and is currently under evaluation by the European Medicines Agency (EMA).

 

The approved therapy follows a new paradigm developed by Prof. Yoram Salomon of the Biological Regulation Department and Prof. Avigdor Scherz of the Plant and Environmental Sciences Department in the framework of photodynamic therapy. It comprises an intravenous infusion of TOOKAD® Soluble, immediately followed by near-infrared laser illumination through thin optic fibers that are inserted into the cancer prostatic tissue, under ultrasound control. Tookad® Soluble was first synthesized in Scherz’s lab from bacteriochlorophyll, the photosynthetic pigment of certain aquatic bacteria that draw their energy supply from sunlight. The drug stays in the patient’s blood circulation until it totally clears 3-4 hours later, and it shows no toxicity. Confined illumination of the diseased tissue activates the circulating drug locally, resulting in the extensive generation of short-lived toxic molecules: oxygen and nitric oxide radicals. These highly reactive molecules initiate rapid occlusion and destruction of the tumor


blood vessels, followed by necrotic death of the entire tumor while sparing nearby structures and their functions. The use of near-infrared illumination, together with the rapid clearance of the drug from the body and the unique non-thermal mechanism of action, makes it possible to safely treat large, deeply embedded cancerous tissue using a minimally invasive procedure. The recent marketing approval was provided to both the drug (TOOKAD® Soluble) and the laser illumination device (Laser), together designated Vascular Targeted Photodynamic Therapy (VTP) with TOOKAD® Soluble.

 

In the currently approved focal therapy setting, TOOKAD® Soluble VTP (TS-VTP) is a day-case procedure lasting approximately 90 minutes. Patients are released a few hours later and can return to normal activities within a few days, with none of the side effects frequently associated with prostate removal by surgery or radiotherapy. This new minimally invasive technology offers a good alternative to patients diagnosed with early-stage prostate cancer. The number of these patients has dramatically increased in the last two decades due to widespread screening relying on levels of prostate specific antigen (PSA). This population faces the dilemma of undergoing the radical treatment of prostate removal with the risk of high morbidity, or remaining under active surveillance with increased risk of further cancer progression.

 

Tookad® Soluble answers an unmet need in providing this category of patients with an appropriate treatment, which combines good efficacy with a preservation of the quality of life.

 

Weizmann institute and Steba Biotech are currently pursuing an extensive oncological research program in collaboration with several clinical groups at Memorial Sloan Kettering Cancer Center in New York City. Four clinical studies for more advanced prostate cancer and other oncological indications stemming from this research are scheduled to start in 2016.

 

Yeda Research and Development Company, the Weizmann Institute’s technology transfer arm, has licensed the drug to Steba Biotech, which manufactures Tookad Soluble. Amir Naiberg, CEO of Yeda: “Our cooperation with Steba covers 20 years of fruitful collaboration. The commitment made by the shareholders of Steba and their personal relationship and effective collaboration with Weizmann Institute scientists and Yeda, have enabled this tremendous accomplishment.”

 

 

 

 

 

Add a comment

 

 

Israeli Startup Emaze Challenges PowerPoint and Releases the Next Generation of Presentations

 

Advanced Tool for Automatically Transforming PowerPoint Slides into Beautifully Designed Presentations in Just Minutes

 

Tel-Aviv, October 15, 2015 - Everyone who presents before an audience knows the difficulties involved in creating a presentation that will impress your audience and convey your message in a compelling manner. Certainly, the templates offered by PowerPoint fall short with their limited and uninspiring designs.

 

Israeli startup emaze aims to solve this problem with it’s new feature, Automaze, which enables users to transform PowerPoint slides into well crafted and beautifully designed presentations – in just a few minutes. The Automaze feature, based on advanced algorithms involving Big Data and Machine Learning, scans the text and photos in the PowerPoint slides and offers a visually stunning version that is best suited to the content of the slides. With this new technology, everyone can present like a pro with an elegant, impressive presentation- created in just minutes with no additional design required.

 

In addition to Automaze, emaze offers innovative presentation making capabilities such as the ability to add in gifs, media, live data, hyperlinking, and more. Video, pan and zoom and 3D transitions, guide your audience through a fascinating visual journey that captures the essence of your narrative.

 

In addition, these presentations can be shared easily via social media, thereby transforming into valuable marketing tools. Each presentation can also be tracked based on how many views it received, where those views occurred, and further segmentation options to meet the needs of each user.

 

 

How does it work?

 

The user enters emaze through the website and uploads their existing PowerPoint presentation and chooses from any of their designer templates. Automaze technology scans the contents of the Powerpoint presentation and then utilizes its extensive database of 10M presentations to beautifully redesign the original presentation. Within minutes, the user receives their new and improved version.

 

Motti Nisani, the founder and CEO of emaze, notes that “we all have occasion to present before some kind of audience – students, investors, potential clients, etc., and we spend hours, even days, designing a presentation that will convey our message and make the desired impact. But, at present, there is a gap between the boring templates offering by PowerPoint and the compelling content that we create. emaze bridges that gap by enabling us within seconds to transform our PowerPoint slides into fantastically designed emaze presentations that captivate audiences by bringing them into our story through dynamic, state-of-the-art features. All of this is possible without any design skills and within literally a few blinks of an eye. In a world in which more than 30 million slide presentations are created every single day, we’re striving to be the Wix of the presentation universe and to set the industry standard for years to come".

 

Is there a cost?

 

emaze is available for free, or with premium upgrades, available to individuals at a cost of $9 a month, or $14 a month for businesses.

 

emaze currently operates out of The Time accelerator, is led by advertising executive Ilan Shiloah, and has 11 employees.

 

 Photo  Silvia Golan

 

 

 

 

 

Add a comment